Chemotherapie und Hemmstoffe der Virusvermehrung

  • M. Staehelin
  • R. Wyler

Zusammenfassung

Definitionsgemäß besteht die Chemotherapie darin, Infektionskrankheiten mit relativ niedermolekularen Stoffen zu behandeln. Diese Substanzen greifen direkt und selektiv den Erreger im infizierten Organismus an, ohne dabei die Körperzellen des Wirts zu schädigen. Die Definition kann außer auf Bakterien und Protozoen — sinngemäß auch auf Virusinfektionen — angewandt werden. Es hat sich in der Praxis gezeigt, daß die meisten gegen Protozoen und Bakterien wirksamen Stoffe auch in vitro eine antimikrobielle Wirkung entfalten. Bei den Virusinfektionen sind die Verhältnisse etwas anders. Nachdem vereinfachte Zellkulturen oder überlebend gehaltene Gewebe in Reagensgläsern als in vitro Systeme zur Vermehrung von Viren herangezogen wurden, fand sich sehr bald, daß eine große Zahl von Substanzen die Virusentwicklung in vitro hemmten, ohne daß sich an den Zellen, mit zwar beschränkten Nachweismethoden, toxische Veränderungen nachweisen ließen. Dieselben Substanzen vermochten aber Virusinfektionen am Tier in untoxischer Dosis nicht zu beeinflussen. In unseren Laboratorien konnte an der Influenza-Virusinfektion festgestellt werden, daß die Übereinstimmung von in vitro und in vivo Aktivität sehr gering war. Wenn man die Literatur durchgeht, kommt man zum Schluß, daß auch andere Bearbeiter dieses Problems die gleichen Erfahrungen machten [10].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Schrifttum

  1. 1.
    Bach, M. K. a. W. E. Magee: Biochemical effects of isatin-β-thiosemicarbazone on development on vaccinia virus. Proc. Soc. Exper. Biol. Med. 110, 565–567 (1962)Google Scholar
  2. 1a.
    Bauer, D. J.: The chemotherapy of ectromelia infection with isatin-β-dialkyl-thiosemicarbazones. Brit. J. Exper. Path. 44, 233–242 (1963)Google Scholar
  3. 1b.
    Bauer, D. J., L. St. Vincent, L. H. Kempe a. A. W. Downie: Prophylactic treatment of smallpox contacts with N-Methylisatin-β-thiosemicarbazone. Lancet II, 494–496 (1963)CrossRefGoogle Scholar
  4. 2.
    Calabresi, P., R. W. Mc Collum a. A. D. Welch: Suppression of infections resulting from a DNA (vaccinia) virus by systemic administration of 5-Iodo-2’-deoxy-uridine. Nature 197, 767–769 (1963)PubMedCrossRefGoogle Scholar
  5. 3.
    Cochran, K. W.: Chemoprophylaxis with diazouracil of poliomyelitis in mice. Science 126, 1115 (1957)PubMedCrossRefGoogle Scholar
  6. 4.
    Cocito, C., A. Prinzie a. P. de Somer: Uptake by mammalian cells of nucleic acids combined with a basic protein. Experientia 18, 218–220 (1962)PubMedCrossRefGoogle Scholar
  7. 5.
    Corrigan, M. J., M. J. Gilkes a. D. St. Clair Roberts: Treatment of dendritic corneal ulceration. Brit. Med. J. 304–305 (1962/II)CrossRefGoogle Scholar
  8. 6.
    Daly, J. J. a. E. Jackson: Vaccinia gangrenosa treated with N-Methylisatin-β-thiosemicarbazone. Brit. Med. J. 5315, 1300 (1962/II)CrossRefGoogle Scholar
  9. 7.
    Eason, R., M. J. Cline a. R. M. S. Smellie: Ribonucleic acid-primed synthesis of RNA following viral infection. Nature 198, 479–480 (1963)CrossRefGoogle Scholar
  10. 8.
    Easterbrook, K. B.: Interference with the maturation of vaccinia virus by isatin-β-thiosemicarbazone. Virology 17, 245–251 (1962)PubMedCrossRefGoogle Scholar
  11. 9.
    Engle, C. G. a. O. C. Liu: Studies on the chemotherapy of viral infections. IV. Anti-influenza activities of glyoxal analogs in vitro and in chick embryo systems. J. Immunol. 89, 531–538 (1962)Google Scholar
  12. 9a.
    Editorial: Antiviral chemotherapy in prevention of smallpox. J. Amer. Med. Ass. 187, 145–146 (1964)Google Scholar
  13. 10.
    Furusawa, E., W. Cutting a. A. Furst: Inhibitory effect of antiviral compounds on viruses in vivo and in mouse ascites cells in vitro. Proc. Soc. Exper. Biol. Med. 112, 617–622 (1963)Google Scholar
  14. 11.
    Garen, A. a. L. M. Kozloff: The initiative bacteriophage infection, in: The Viruses, Vol. 2 (F. M. Burnet and W. M. Stanley, Eds.), p. 203–236, Academic Press, New York 1959Google Scholar
  15. 12.
    Ginsberg, H. S. a. F. L. Horsfall: Therapy of infection with pneumonia virus of mice (PVM). Effect of a polysaccharide on the multiplication cycle of the virus and on the course of viral pneumonia. J. Exper. Med. 93, 161–171 (1951)CrossRefGoogle Scholar
  16. 12a.
    Gordon, D. M. a. D. A. Karnofsky: Chemotherapy of herpes simplex keratitis. Amer. J. Ophthal. 55, 229–234 (1963)PubMedGoogle Scholar
  17. 13.
    Gordon, M. P. a. M. Staehelin: Studies on the incorporation of 5-Fluorouracil into a virus nucleic acid. Biochem. Biophys. Acta 36, 351–361 (1959)PubMedCrossRefGoogle Scholar
  18. 14.
    Gottschalk, A.: Neuramidase. Its substrate and mode of action. Adv. Enzym. 20, 135–146 (1958)Google Scholar
  19. 14a.
    Hansson, O., B. Vahlquist: Vaccinia grangrenosa and compound 33 T 57. Lancet II, 687 (1963)CrossRefGoogle Scholar
  20. 14b.
    Havener, W. H. a. J. Wachtel: IDU therapy of herpetic keratitis. Amer. J. Ophthal. 55, 234–237 (1963)PubMedGoogle Scholar
  21. 15.
    Hopkin, E. J., A. M. Pye, M. Solomon a. S. Solomon: Controlled trial of Virugon in treatment of measles. Brit. Med. J. 5262, 1263–1264 (1961/II)CrossRefGoogle Scholar
  22. 16.
    Horsfall, F. L.: Inhibition of multiplication, in: The Viruses, Vol. 3, (F. M. Burnet and W. M. Stanley, Eds.), p. 195–224. Academic Press, New York 1959Google Scholar
  23. 17.
    Horsfall, F. L. a. I. Tamm: Chemotherapy of viral and rickettsial diseases. Ann. Rev. Microbiol. 11, 339–370 (1957)CrossRefGoogle Scholar
  24. 17a.
    Isaacs, A., R. A. Cox a. 2. Rotem: Foreign nucleic acids as the stimulus to make interferon. Lancet II, 113–116 (1963)CrossRefGoogle Scholar
  25. 18.
    Ishida, N.: One decade of antiviral studies. Dpt. of Bacteriology, School of Medicine, Tohoku University, Sendai (Japan) 1962Google Scholar
  26. 19.
    Kaufman, H. E. a. E. D. Maloney: IDU and hydrocortisone in experimental herpes simplex keratitis. Arch. Ophthal. 68, 396–398 (1962)PubMedCrossRefGoogle Scholar
  27. 20.
    Kaufman, H. E. a. E. D. Maloney: Therapeutic anti-viral activity in tissue culture. Proc. Soc. Exper. Biol. Med. 112, 4–7 (1963)Google Scholar
  28. 21.
    Kleinschmidt, H.: Versuche mit ABOB zur Prophylaxe und Therapie bei Masern und Varizellen. Münch. med. Wschr. 104, 2294–2296 (1962)PubMedGoogle Scholar
  29. 22.
    Kradolfer, F. u. R. Wyler: Photoaktivierbare Antiviruswirkung von Porphyrinen. Z. Hyg. Infekt.-Kr. 143, 416–428 (1957)CrossRefGoogle Scholar
  30. 23.
    Levy, H. D. a. V. H. Haas: Alteration of the course of lymphocytic choriomeningitis in mice by certain antimetabolites. Virology 5, 401–407 (1958)PubMedCrossRefGoogle Scholar
  31. 24.
    Lewis, u. J., E. L. Rickes, D. E. Williams, L. Mc Clelland a. N. G. Brink: Studies on the antiviral agent Helenine. Purification and evidence for ribonucleoprotein nature. J. Amer. Chem. Assoc. 82, 5178–5182 (1960)CrossRefGoogle Scholar
  32. 25.
    Liu, O. C., J. E. Carter, R. G. Malsberger, A. N. de Sanctis a. B. Hampil: Studies on the chemotherapy of viral infections. II. The effect of caprochlorone on influenza virus infection in mice. J. Immunol. 82, 222–227 (1957)Google Scholar
  33. 26.
    Liu, O. a. C. G. Engle: Effect of Xenaldial on herpes simplex virus. Antibiot. et Chemother. 11, 76–87 (1963)Google Scholar
  34. 27.
    Liu, O. C. a. R. J. Ferlando: Comparison of anti-influenza effects of four synthetic compounds. Antibiot. et Chemother. 11, 308–317 (1963)Google Scholar
  35. 28.
    Lwoff, A.: Bacteriophage as a model of host-virus relationship. In: The Viruses, Vol. 2 (F. M. Burnet and W. M. Stanley, Eds.), p. 187–201, Academic Press, New York 1959Google Scholar
  36. 29.
    Lwoff, A. et M. Lwoff: Sur les facteurs du développement viral et leur rôle dans l’évolution de l’infection. Ann. Inst. Pasteur 98, 173–203 (1960); Les événements cycliques du cycle viral. III. Discussion. Ann. Inst. Pasteur 101, 490–504 (1961)Google Scholar
  37. 29a.
    Lwoff, A.: Factors influencing the evolution of viral diseases at the cellular level and in the organism. Bact. Rev. 23, 109–124 (1959)PubMedGoogle Scholar
  38. 30.
    Magrassi, F.: Studies on new synthetic antiviral drugs: ketoaldehydic derivates of biphenyl: aspects in experimental and clinical fields. Antibiot. et Chemother. 11, 50–75 (1963)Google Scholar
  39. 31.
    Matthews, R. E. F. a. J. D. Smith: The chemotherapy of viruses. Adv. Virus Res. 3, 49–148 (1955)PubMedCrossRefGoogle Scholar
  40. 31a.
    Maxwell, R.: Treatment of corneal disease with 5-iodo-2’deoxyuridine (IDU). A clinical evaluation of 500 cases. Amer. J. Ophthal. 55, 237–238 (1936)Google Scholar
  41. 31b.
    Meiklejohn, G., W. P. Mc Cann a. S. Shkolnik: Field trial with ABOB (SK8898-A) as a prophylactic agent against influenza A2 and adenovirus infection. Military Medicine 890–894 (1963)Google Scholar
  42. 32.
    Melander, B.: Correlation between antiviral activity in experimental animals and man. Antibiot. et Chemother. 11, 130–133, 372–385 (1963)Google Scholar
  43. 33.
    Melnick, J. L., D. Gowther a. J. Barrera-Oro: Rapid development of drug resistant mutants of poliovirus. Science 134, 557–558 (1961)PubMedCrossRefGoogle Scholar
  44. 34.
    Munyon, W. a. N. P. Salzmann: The incorporation of 5-fluoro-uracil into polio virus RNA. Fed. Proc. 21, 462 (1962); Virology 18, 95–101 (1962)Google Scholar
  45. 35.
    O’Dell, Th., H. N. Wright a. R. N. Bieter: Chemotherapeutic activity of nucleic acids and high protein diets against the infection caused by the MM virus in mice. J. Pharmacol. Exper. Ther. 107, 232–240 (1953)Google Scholar
  46. 36.
    Pereira, H. G.: The cytopathic effect of animal viruses. Advanc. Virus Res. 8, 245–285 (1961)CrossRefGoogle Scholar
  47. 37.
    Powell, H. M., D. N. Walcher a. C. Mast: Antiviral action of statolon against Coxsackie A 21 (Coe) virus. Antibiot. and Chemother. 12, 337–341 (1962)Google Scholar
  48. 38.
    Reich, E., R. M. Franklin, A. J. Shatkin a. E. L. Tatum: Effect of actinomycin D on cellular nucleic acid synthesis and virus production. Science 134, 556–557 (1961); Action of actinomycin D on animal cells and viruses. Proc. Nat. Acad. Sci., U.S., 48, 1238–1245 (1962)Google Scholar
  49. 39.
    Rolly, H.: Gezielte Chemotherapie bei Virusinfektionen. Erfahrungen bei der Behandlung des Herpes corneae mit 5-Joddesoxyuridin. Münch. med. Wschr. 105, 149–151 (1963)PubMedGoogle Scholar
  50. 40.
    Sadler, P. W., D. G. O’Sullivan a. D. J. Bauer: A study of substances of potential value in the treatment of Pox virus and Entero virus infections. Antibiot. et Chemother. 11, 403–412 (1963)Google Scholar
  51. 40a.
    Sadler, P. W.: Chemotherapy of viral diseases. Pharm. Rev. 15, 407–447 (1963)PubMedGoogle Scholar
  52. 41.
    Shatkin, A. J.: Actinomycin inhibition of ribonucleic acid synthesis and poliovirus infection of HeLa cells. Biochem. Biophys. Acta 61, 310–313 (1962)PubMedGoogle Scholar
  53. 42.
    Shope, R. E.: An antiviral substance from penicillium funiculosum. 1. Effect upon infection in mice with Swine influenza virus and Col SK virus. J. Exper. Med. 97, 601–626 (1953)CrossRefGoogle Scholar
  54. 43.
    Staehelin, M.: Experimental and biochemical basis for a chemoprophylaxis and chemotherapy of virus infections. Progr. med. Virol. 2, 1–42 (1959)Google Scholar
  55. 44.
    Staehelin, M.: Chemical modifications of virus infectivity: Reactions of Tobacco Mosaic Virus and its nucleic acid. Experientia 60, 473–483 (1960)CrossRefGoogle Scholar
  56. 45.
    Tamm, I.: Chemotherapy and virus infection. Viral and Rickettsial Infections of Man, pp. 156–171, 3rd ed.. J. B. Lippincott Comp., Philadelphia 1959Google Scholar
  57. 46.
    Tamm, I.: Principles of antivirus chemotherapy. Antibiot. and Chemother. 12, 423–439 (1962)Google Scholar
  58. 47.
    Thely, M., J. Choay, L. Dhennin et L. Dhennin: Virologie-Virostase induite in vivo par des acides ribonucléiques non-infectieux. Compt. rend. Acad. Sci. 256, 1048–1050 (1963)Google Scholar
  59. 48.
    Thiel, R. u. A. Wacker: Behandlung der Keratitis herpetica mit thyminanalogen Verbindungen. Klin. Mbl. Augenheilk. 141, 94–108 (1962)Google Scholar
  60. 49.
    Underwood, G. E.: Activity of l-β-D-arabinofuranosylcytosine hydrochloride against Herpes simplex keratitis. Proc. Soc. Exper. Biol. (N.Y.) 111, 660–664 (1962)Google Scholar
  61. 50.
    Vainio, T., J. D. Judah a. G. Bjotvedt: Mechanism of cellular damage by virus: a study of antihistaminic drugs. I. Murine hepatitis virus and liver explant cultures. Exper. & Mol. Pathol. 1, 15–26 (1962); II. Murine hepatitis virus and mouse macrophages. Exper. & Mol. Pathol. 1, 27–36 (1962)CrossRefGoogle Scholar
  62. 51.
    Walker, D. L. a. W. D. Boring: Factors influencing host-virus interactions. III. Further studies on the alterations of Coxsackie virus infection in adult mice by environmental temperature. J. Immunol. 80, 39–44 (1958)PubMedGoogle Scholar
  63. 52.
    Ward, P. A. a. A. G. Johnson: Studies on the adjuvant action of bacterial endotoxin on antibody formation. II. Antibody formation in Cortisone treated rabbits. J. Immunol. 85, 428–434 (1959)Google Scholar
  64. 53.
    Watson, G. I.: Virugon (Flumidin) no benefit in two respiratory diseases. Brit. Med. J. 5215, 1785–1786 (1960/II)CrossRefGoogle Scholar
  65. 54.
    Weinstein, L.: Corticotropin and corticosteroids in human viral infections. Med. Clin. N. Amer. 46, 1141–1161 (1962)Google Scholar
  66. 55.
    Welsch, M.: Le problème de la chimiothérapie des infections à virus. Chemotherapia 1, 1–18 (1960)CrossRefGoogle Scholar
  67. 56.
    Wheatly, D.: A trial of flumidin (Virugon) in common virus infections seen in general practice. Antibiot. et Chemother. 11, 386–393 (1963)Google Scholar
  68. 57.
    Wittmann, H. O.: Proteinuntersuchungen an Mutanten des Tabakmosaikvirus als Beitrag zum Problem des genetischen Codes. Z. Vererbungsl. 93, 491–530 (1962)CrossRefGoogle Scholar
  69. 58.
    Wöhler, F.: Behandlung der Poliomyelitis und Virusmeningoenzephalitis mit Cortison and Butazolidin. Med. et Hyg. 18, 708–709 (1960)Google Scholar
  70. 59.
    Wyler, R. u. F. Kradolfer: Ausdruck unspezifischer Resistenzverschiebung im Virustiter infizierter Mäuseorgane. Schweiz. Z. Path. 21, 1018–1023 (1958)Google Scholar
  71. 60.
    Yorio Hinuma, Y. Satos, M. Chiba, Y. Kosaka a. M. Kuroya: Studies on antiviral antibiotics from streptomyces. X. Effect of myxoviromycin upon infection with influenza virus in mice. Jap. J. Microbiol. 2, 117–125 (1958)Google Scholar

Copyright information

© J. F. Lehmanns Verlag München 1965

Authors and Affiliations

  • M. Staehelin
  • R. Wyler

There are no affiliations available

Personalised recommendations